HK1025742A1 - Sublingual composition containing apomorphine for diagnosing functional impotence - Google Patents

Sublingual composition containing apomorphine for diagnosing functional impotence

Info

Publication number
HK1025742A1
HK1025742A1 HK00104970A HK00104970A HK1025742A1 HK 1025742 A1 HK1025742 A1 HK 1025742A1 HK 00104970 A HK00104970 A HK 00104970A HK 00104970 A HK00104970 A HK 00104970A HK 1025742 A1 HK1025742 A1 HK 1025742A1
Authority
HK
Hong Kong
Prior art keywords
composition containing
containing apomorphine
sublingual composition
diagnosing functional
functional impotence
Prior art date
Application number
HK00104970A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Alvaro Morales
Jeremy P W Heaton
Michael A Adams
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22868404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1025742(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of HK1025742A1 publication Critical patent/HK1025742A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK00104970A 1994-04-22 1998-12-24 Sublingual composition containing apomorphine for diagnosing functional impotence HK1025742A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23125094A 1994-04-22 1994-04-22
HK98115585A HK1014239A1 (en) 1994-04-22 1998-12-24 Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
HK1025742A1 true HK1025742A1 (en) 2000-11-24

Family

ID=22868404

Family Applications (2)

Application Number Title Priority Date Filing Date
HK98115585A HK1014239A1 (en) 1994-04-22 1998-12-24 Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction
HK00104970A HK1025742A1 (en) 1994-04-22 1998-12-24 Sublingual composition containing apomorphine for diagnosing functional impotence

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK98115585A HK1014239A1 (en) 1994-04-22 1998-12-24 Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction

Country Status (16)

Country Link
US (3) US5770606A (xx)
EP (2) EP0978282B1 (xx)
JP (1) JP3310982B2 (xx)
KR (1) KR100374924B1 (xx)
AT (2) ATE312609T1 (xx)
AU (1) AU703608B2 (xx)
CA (1) CA2188385C (xx)
DE (3) DE69534693T2 (xx)
DK (2) DK0978282T3 (xx)
ES (2) ES2256999T3 (xx)
GR (1) GR3033084T3 (xx)
HK (2) HK1014239A1 (xx)
LU (1) LU90856I2 (xx)
NL (1) NL300072I1 (xx)
PT (1) PT758895E (xx)
WO (1) WO1995028930A1 (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
AU751565B2 (en) * 1995-06-13 2002-08-22 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
PT996447E (pt) * 1997-05-19 2006-12-29 Zonagen Inc Terapia combinada para moldular a resposta sexual humana
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
KR20010021625A (ko) 1997-07-09 2001-03-15 추후보정 개선된 남성발기 기능장애 치료방법 및 그 조성물
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1035833B1 (en) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
EP1235563A2 (en) 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7577475B2 (en) * 1999-04-16 2009-08-18 Cardiocom System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
EE05315B1 (et) 1999-09-03 2010-08-16 Eli Lilly And Company Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
WO2001076602A1 (en) * 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
FR2813193B1 (fr) * 2000-08-25 2003-08-15 Pelvipharm Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002235129A1 (en) 2000-11-15 2002-05-27 Tap Pharmaceutical Products Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1224933A1 (en) * 2001-01-19 2002-07-24 Sanofi-Synthelabo New combination of active ingredients containing alfuzosine and apomorphine
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
DK1471890T3 (da) * 2002-02-07 2007-01-08 Pharmacia Corp Farmaceutisk doseringsform til mukös afgivelse
CN1720054A (zh) * 2002-03-19 2006-01-11 布雷恩及比扬德生物科技公司 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (en) * 2002-10-10 2004-04-10 Queen's University At Kingston Treatment of sexual dysfunction
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
CN102772357B (zh) * 2003-03-31 2014-12-31 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
AR044782A1 (es) * 2003-06-17 2005-10-05 Ortho Pharma Corp Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina
PL2450041T3 (pl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Ulepszony żel zawierający testosteron do zastosowania do leczenia hipogonadyzmu
CA2637838A1 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
DK2442650T3 (en) 2009-06-12 2015-12-07 Cynapsus Therapeutics Inc sublingual apomorphine
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
MX2016006087A (es) * 2013-11-11 2016-08-12 Impax Laboratories Inc Formulaciones de desintegracion rapida y metodos de uso.
US10413517B2 (en) * 2014-06-12 2019-09-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine

Also Published As

Publication number Publication date
US5770606A (en) 1998-06-23
EP0758895A1 (en) 1997-02-26
KR970702041A (ko) 1997-05-13
DE69514794T2 (de) 2000-07-27
WO1995028930A1 (en) 1995-11-02
ATE312609T1 (de) 2005-12-15
DK0758895T3 (da) 2000-06-13
EP0758895A4 (en) 1997-04-09
LU90856I2 (fr) 2002-01-24
DE10199068I2 (de) 2004-05-06
NL300072I1 (nl) 2002-02-01
DE69534693T2 (de) 2006-08-31
JP3310982B2 (ja) 2002-08-05
EP0978282A2 (en) 2000-02-09
GR3033084T3 (en) 2000-08-31
AU2295895A (en) 1995-11-16
AU703608B2 (en) 1999-03-25
DK0978282T3 (da) 2006-04-10
EP0758895B1 (en) 2000-01-26
KR100374924B1 (ko) 2003-07-22
JPH09512273A (ja) 1997-12-09
DE10199068I1 (de) 2003-06-05
EP0978282B1 (en) 2005-12-14
ES2256999T3 (es) 2006-07-16
HK1014239A1 (en) 1999-09-24
ES2143049T3 (es) 2000-05-01
EP0978282A3 (en) 2000-06-07
CA2188385C (en) 2000-07-11
US5985889A (en) 1999-11-16
PT758895E (pt) 2000-05-31
US6200983B1 (en) 2001-03-13
CA2188385A1 (en) 1995-11-02
DE69534693D1 (de) 2006-01-19
ATE189121T1 (de) 2000-02-15
DE69514794D1 (de) 2000-03-02

Similar Documents

Publication Publication Date Title
HK1025742A1 (en) Sublingual composition containing apomorphine for diagnosing functional impotence
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
ATE162947T1 (de) Neue verwendungen für il-10
GB8625103D0 (en) Disinfectant compositions
MX9701088A (es) Composicion de recubrimiento inhibidora de corrosion para metales.
NZ333475A (en) Microemulsion all purpose liquid cleaning compositions containing 0.05% to 5.0% of an acaricidal agent
GB9519110D0 (en) Improvements in or relating to chemical compositions
BG101714A (en) Improvements in the function of the endometrium or in functions related to it
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
GB2187097B (en) Disinfectant compositions
WO1999017711A3 (en) Autophobic hairspray compositions
AU565844B1 (en) Composition for protecting teeth against decalcification
CA2216749A1 (en) Oral care compositions comprising liquid polyoxyalkylene compounds as solubilizers/gelling agents
PL342165A1 (en) Antienzymic composition containing ethylenediamino disuscinic acid
GB8607160D0 (en) Disinfecting compositions
AU7116587A (en) Anti-corrosion composition
GR3005963T3 (xx)
RU97113900A (ru) Состав для профилактики и лечения кариеса зубов
GB8728875D0 (en) Disinfecting composition for humanveterinary use
GB9020542D0 (en) Improvements in or relating to chemical compositions
GB9304732D0 (en) Improvements in or relating to germicidal compositions
GB8924185D0 (en) Acid neutralising composition
ZA876374B (en) Composition for disinfecting water
IL95087A0 (en) Neutralizing composition for mustard gas comprising an iodine containing compound
PH30823A (en) Novel compositions containing hyaluronic acid.

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: ADDITION OF EARLIER APPLICATION UNDER S.22: 24.12.1998 98115585.2

Effective date: 20051123

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100421